Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Just Gave Pancreatic Cancer Patients Early Access To A Pill That Doubled Survival Time

The Food and Drug Administration has authorized early expanded access to a new pill called daraxonrasib, developed by Revolution Medicines, giving patients with advanced pancreatic cancer a chance to receive the experimental treatment while it awaits full regulatory approval, in a move the agency completed just two days after receiving the request. Pancreatic cancer is among the most lethal cancers in existence, with a five-year survival rate of only about 3 percent for the most common metastatic form, and until now new treatment options have been frustratingly scarce for patients who have already tried conventional therapies. The speed of the FDA’s response was itself notable: the regulator received Revolution Medicines’ expanded access application on April 28th and signed it on April 30th, and the FDA Commissioner said the two-day turnaround reflects the agency’s commitment to getting promising treatments to patients with life-threatening conditions without delay. The pill works by targeting a protein called RAS, which is mutated in the majority of pancreatic cancer tumors and had for decades been considered essentially undruggable.

In a closely watched phase 3 trial called RASolute 302, daraxonrasib produced results the oncology community called unprecedented: patients taking the pill survived a median of 13.2 months compared to 6.7 months for those receiving standard chemotherapy, a 60 percent reduction in the risk of death. The drug is taken orally once a day and was generally well tolerated in the trial, with no new safety signals reported. Daraxonrasib has also received Breakthrough Therapy and Orphan Drug designations from the FDA, and the company says it intends to submit a full new drug application under the FDA’s national priority program. Revolution Medicines said it is moving as quickly as possible to ensure safe and equitable access to the drug for eligible patients across the United States.

Source: https://www.reuters.com/legal/litigation/us-fda-authorizes-early-access-revolutions-pancreatic-cancer-pill-2026-05-01/

PrevPreviousCommunities Across America Are Banning AI Data Centers And The Number Just Jumped From 8 To 78
NextA Kitten Found Covered Head To Tail In Industrial Glue Just Made A Full Recovery And Has A New HomeNext

Recent Articles

Happy News

Happy 100th Birthday Sir David Attenborough, The Greatest Natural Storyteller Who Ever Lived

May 8, 2026

On May 8, 2026, Sir David Attenborough turns 100 years old and he is still on our television screens. Many folks online have jokingly pointed out that Attenborough can no longer play with legos due to the toy’s 100 year old age limit. His most recent BBC series, Secret Garden,

Read More
Happy News

Queen Camilla Just Reunited Winnie The Pooh With A Friend Missing Since The 1930s

May 8, 2026

During the British royal family’s state visit to the United States this week, Queen Camilla made a detour from the political events and state dinners to visit the New York Public Library, where she attended a literary celebration and quietly accomplished something that has been waiting to happen for nearly

Read More
Happy News

Scientists Reviewed 217 Trials To Find The Best Exercise For Knee Arthritis Pain

May 7, 2026

A sweeping review of 217 clinical trials involving more than 15,000 participants has produced the clearest guidance yet on which types of exercise are most effective for people living with knee osteoarthritis, and the answer turns out to be accessible, inexpensive, and available to almost anyone: walking, cycling, and swimming.

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.